Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07135323 · ClinicalTrials.gov registry record

AvertD Post-Approval Study

A clinical trial of Opioid Use Disorder, sponsored by Prescient Medicine Holdings.

Recruiting
Registry status
4,000
Enrollment target
1
Study location

NCT07135323 is a study of Opioid Use Disorder that is actively recruiting participants, run by Prescient Medicine Holdings. The registered enrollment target is 4,000 participants, below the 4,641-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07135323, a study of Opioid Use Disorder, is actively recruiting participants, sponsored by Prescient Medicine Holdings.

RECRUITING
Registry status
4,000 participants
Enrollment target
1
Study location

Study Summary

A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population

Conditions Studied

Interventions

  • GENETIC Opioid Used Disorder Risk Assessment

Study Locations (1)

Indiana

  • Concentrics Research - Indianapolis

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2024-11-15
Est. Completion 2031-11

Sponsor

Prescient Medicine Holdings

1 total trials

What the Registry Record Tells You About NCT07135323

The ClinicalTrials.gov registry entry for NCT07135323 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,641-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (14% lower). The listed sponsor is Prescient Medicine Holdings, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Opioid Used Disorder Risk Assessment is the first listed.

NCT07135323 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT07135323 about?

NCT07135323 is a clinical study titled "AvertD Post-Approval Study". A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population

What is the current status of trial NCT07135323?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2024-11-15. Estimated completion is 2031-11.

What conditions does trial NCT07135323 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT07135323?

The interventions under investigation include: Opioid Used Disorder Risk Assessment (GENETIC).

Who is sponsoring clinical trial NCT07135323?

This trial is sponsored by Prescient Medicine Holdings, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07135323 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.